Physician profile
Robert M Sutherland
NPI 1033112933
$6,019.82
in general payments reported to CMS, 2019-2025
23 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $138 · 2021: $927 · 2022: $1,902 · 2023: $1,396 · 2024: $590 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875 · Travel and Lodging: $486 · Education: $50.86 · Gift: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.70 |
| Travel and Lodging | $485.83 |
| Education | $50.86 |
| Gift | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,613.21 | 2019-2025 | Proclaim, Octrode, Eterna |
| Genesys Orthopedics Systems, L.L.C. | $815.08 | 2023 | Sacroiliac Joint Fusion System |
| Medtronic, INC. | $375.49 | 2021-2024 | Intellis Adaptivestim |
| Nevro Corp. | $205.39 | 2019-2022 | |
| Boston Scientific Corporation | $180.10 | 2025 | General - Therapies, General - Pain Management, Wavewriter Alpha Prime 16 |
| Mml US, INC. | $160.14 | 2024 | Reactiv8 |
| Daiichi Sankyo INC. | $114.23 | 2019 | |
| Scilex Pharmaceuticals INC. | $105.12 | 2019-2025 | |
| Avanos Medical | $104.44 | 2020-2021 | |
| Hydrocision, INC. | $73.90 | 2024 | Tenjet |
| Curonix LLC | $50.86 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Horizon Therapeutics Plc | $29.34 | 2021-2022 | |
| Abbvie INC. | $22.93 | 2022 | |
| Stimwave Technologies Incorporated | $21.26 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.93 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $18.93 | 2022 | |
| Allergan, INC. | $18.61 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.33 | 2021 | |
| Assertio Therapeutics, INC. | $16.52 | 2020 | |
| Relievant Medsystems, INC. | $14.63 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.48 | 2019 | |
| Pfizer INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.